openPR Logo
Press release

Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022

12-01-2022 04:05 AM CET | Health & Medicine

Press release from: Global Insight Services

Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022

Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022

Graft Versus Host disease (GVHD) is an immune mediated systemic disorder associated with complex interaction between donor and recipient adaptive immunity. It is a common complication after hematopoietic stem cell transplant (HCT), here the graft recognizes the host as a foreign and attack the recipient's body cell. GvHD is of two types: acute GvHD - which develops within 100 days of transplantation and chronic GvHD - which develops after 100 days of transplantation.

To know more about Graft Versus Host Disease (GVHD) 's pipeline, visit - https://www.globalinsightservices.com/reports/graft-versus-host-disease-gvhd-drug-pipeline-landscape-2022/

GvHD occurs after the bone marrow transplants and stem cell transplants. Following are the other occurrences of GvHD - allogenic bone transplantation, solid organs that are rich in lymphoid cells and un-irradiated blood.

Symptoms of GvHD range from mild to severe. Common acute symptoms include abdominal pain or cramps, nausea, vomiting, diarrhoea, jaundice, skin rash, itching, redness on areas of the skin and increased risk for infections. Chronic symptoms include dry eyes, burning sensation, fatigue, joint pains, shortness of breath, wight loss, etc.,

GvHD is diagnosed through imaging - X-ray abdomen, CT scan abdomen and chest, PET scan and MRI. Other diagnosis involves liver function tests, liver biopsy and capsule endoscopy.

To Remain 'Ahead' Of Your Competitors, Request for A Sample - https://www.globalinsightservices.com/request-sample/GIS31106

Key Players
9 Meters Biopharma Inc
Abbisko Cayman Limited
Accro BioScience (Suzhou) Co Ltd
Actitrexx GmbH
Adienne Pharma & Biotech SA
Alphamab Oncology
AltruBio Inc
Amcyte Pharma Inc
AnaMar AB
AnaptysBio Inc
ASC Therapeutics Inc
AstraZeneca Plc
Avalon GloboCare Corp

Report Segmentation
Assessment by Stage of Development
Assessment by Companies
Assessment by Target
Assessment by Mechanism of Action
Assessment by Molecule Type
Assessment by Route of Administration

Get Customized Report as Per Your Requirement - https://www.globalinsightservices.com/request-customization/GIS31106

Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources.

For In-Depth Competitive Analysis, Purchase this Report - https://www.globalinsightservices.com/inquiry-before-buying/GIS31106

With Global Insight Services, you receive:
• 10-year forecast to help you make strategic decisions
• In-depth segmentation which can be customized as per your requirements
• Free consultation with lead analyst of the report
• Excel data pack included with all report purchases
• Robust and transparent research methodology

Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm
headquartered in Delaware, US. We are committed to providing our clients
with highest quality data, analysis, and tools to meet all their market research
needs. With GIS, you can be assured of the quality of the deliverables, robust
and transparent research methodology, and superior service.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022 here

News-ID: 2829539 • Views:

More Releases from Global Insight Services

Glp-1 Agonist Market To Surge From $53 BN To $264.9 BN By 2034 At 17.5% Cagr. Key Players: Hanmi Pharmaceutical, Zydus Cadila, Oramed Pharmaceuticals.
Glp-1 Agonist Market To Surge From $53 BN To $264.9 BN By 2034 At 17.5% Cagr. Ke …
Market Overview GLP-1 Agonist Market is rapidly evolving as the demand for advanced diabetes and obesity treatments continues to rise globally. These drugs, known as glucagon-like peptide-1 receptor agonists, help improve insulin secretion, reduce glucagon levels, and enhance satiety-making them a powerful solution for type 2 diabetes and weight management. With diabetes and obesity reaching unprecedented levels, the GLP-1 Agonist Market stands at the forefront of therapeutic innovation. Growing patient awareness,
Financial Risk Management Software Market To Grow From $24.5 BN To $47.8 BN By 2034 At 6.9% Cagr. Key Players: Activeviam, Sas Risk Management, Fiserv.
Financial Risk Management Software Market To Grow From $24.5 BN To $47.8 BN By 2 …
Market Overview Financial Risk Management Software Market is evolving rapidly as financial institutions and enterprises navigate increasingly complex global uncertainties. With tightening regulations and growing exposure to market volatility, organizations are turning toward advanced digital solutions that help identify, assess, and mitigate financial risks in real time. The Financial Risk Management Software Market integrates AI, machine learning, predictive analytics, and cloud technologies to enhance credit, liquidity, operational, and market risk insights.
Esg Risk Management Market To Rise From $268.8 MN To $1,032.2 MN By 2034 At 14.4% Cagr. Key Players: Sustainalytics, Reprisk, Arabesque.
Esg Risk Management Market To Rise From $268.8 MN To $1,032.2 MN By 2034 At 14.4 …
Market Overview ESG Risk Management Market is gaining significant momentum as businesses increasingly prioritize sustainability and ethical governance in their operations. Valued at $268.8 million in 2024, the market is projected to surge to $1,032.2 million by 2034, growing at a CAGR of 14.4%. The ESG Risk Management Market encompasses technologies and services designed to identify, monitor, and mitigate environmental, social, and governance risks, ensuring businesses operate responsibly while complying with
Enterprise Firewall Market To Grow From $15 BN (2024) To $40.3 BN (2034) At 10.4% Cagr. Key Players: Sonicwall, Watchguard, Palo Alto Networks.
Enterprise Firewall Market To Grow From $15 BN (2024) To $40.3 BN (2034) At 10.4 …
Market Overview Enterprise Firewall Market is witnessing substantial growth as organizations worldwide prioritize safeguarding their digital infrastructure from sophisticated cyber threats. Valued at $15 billion in 2024, the market is projected to reach $40.3 billion by 2034, expanding at a CAGR of 10.4%. The Enterprise Firewall Market encompasses solutions designed to secure enterprise networks by monitoring, filtering, and blocking unauthorized access while ensuring uninterrupted business operations. With the surge in cyberattacks,

All 5 Releases


More Releases for GvHD

Graft Versus Host Disease (GvHD) Market Expected to Expand at a Steady 2022-2028 …
Coherent Market Insights have added a new research study on Title Graft Versus Host Disease (GvHD) Market, Global Outlook and Forecast 2022-2028 with detailed information & Key Players Such as Gvhd market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd. The Study provides in-depth comprehensive analysis includes Clear Market definitions, classifications, manufacturing processes, cost structures, development policies and plans. The
Graft Versus Host Disease GvHD Treatment Market Investment Research Report 2016- …
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain
Graft Versus Host Disease GvHD Treatment Market Revenue and Value Chain 2016-202 …
Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain
Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2017, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape. Graft-versus-host disease (GVHD) is a complication that can occur after
Graft Versus Host Disease (GvHD) Market - Global Industry Analysis 2024
During any transplant of stem cell and bone marrow some complications arises that may be mild or severe, those are the graft versus host disease (Gvhd) they occur especially in immune-compromised patients. During cancer treatment, the radioactive agents or the chemicals affects the healthy cells along with the cancer cells. Reconstruction of body cells affected during cancer treatment can be fixed using stem cell and bone marrow transplant. Following a
Fresh exploration on Graft versus Host Disease (GVHD)
DelveInsights Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023-United States report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023). The report also includes